Abstract Aims/hypothesis: Phosphoenolpyruvate carboxykinase (PCK) is the key enzyme involved in the regulation of gluconeogenesis. The aim of this study was to identify genetic polymorphisms in potential candidate genes for type 2 diabetes by sequencing all exons in the PCK genes (PCK1 and PCK2), and examining the association with type 2 diabetes and diabetic phenotypes in a Korean population (775 type 2 diabetic patients and 316 normal control subjects). Materials and methods: Twenty-two polymorphisms in PCK1 and PCK2 were identified in a Korean population (n=24) by direct DNA sequencing. The TaqMan genotyping method was applied for genotyping] the remainder of the study population. Associations of PCK polymorphisms with the risk of type 2 diabetes and diabetic phenotypes were analysed using logistic and multiple regressions, adjusting for age, sex and BMI. Results: Although no significant associations between the genetic polymorphisms in PCK genes and the risk of type 2 diabetes were detected, in further haplotype analysis, one of the common haplotypes, PCK1 ht3, revealed susceptibility to type 2 diabetes (p=0.006). One 3′ untranslated region (UTR) single nucleotide polymorphism (SNP) also showed an association with HDL levels among nondiabetic control subjects: individuals homozygous for the major allele (T/T) had the lowest HDL level (1.11± 0.32 mmol/l), heterozygotes (T/C) had an intermediate level (1.27±0.37 mmol/l), and those homozygous for the minor allele (C/C) had the highest level (1.39±0.28 mmol/l) (p=0.000003). This 3′ UTR SNP was also associated with triglyceride levels, with a lower triglyceride level observed among individuals who were homozygous for the minor allele (C/C) than among those who were not. Conclusions/ interpretation: The strong genetic association of HDL and triglyceride levels with variation/haplotype information identified in this study would be useful for further genetic epidemiological studies of this important gene.
Introduction
Phosphoenolpyruvate carboxykinases (PCKs) mainly function as enzymes that help to regulate gluconeogenesis, and have been implicated as candidate genes for type 2 diabetes mellitus. PCKs are found in the cytosol (encoded by PCK1; MIM 261680) and the mitochondria (encoded by PCK2; MIM 261650) [1, 2] . The similar gene structures and the amino acid sequence homology of 68-70% between the cytosolic PCK1 and the mitochondrial PCK2 [3] suggest that they are derived from a common ancestor gene. The activity of PCK1 (on chromosome 20q13.31) is controlled by the rate of transcription of its gene, which is regulated by insulin, glucocorticoids, cAMP and diet, to adjust glucose production to meet physiological requirements [4] , whereas PCK2 (on chromosome 14q11.2) seems to be constitutively active [4] . It has been proposed that PCK1 is best suited to gluconeogenesis from amino acids and that mitochondrial PCK2 best serves gluconeogenesis from lactate [4] . Recent evidence suggests that PCK may primarily function as an integrator of hepatic energy metabolism rather than as a determinant of gluconeogenesis [1, 5, 6] .
Previous studies had indicated that the PCK1 region on chromosome 20q has a genetic linkage to type 2 diabetes. Using affected-sib-pair methods, significant results were obtained in the 20q13 region, in the vicinity of the PCK1 locus [7] . This was also reported as a candidate region for insulin resistance [8] . It is noteworthy that two other diabetes-susceptibility genes also map to chromosome 20q, both of which are centromeric to the PCK1 locus, namely MODY1, which causes a subtype of MODY, and the gene encoding the agouti signalling protein, non-agouti homologue (mouse) (ASIP), which is the human homologue of a murine gene responsible for an obesity-diabetes syndrome in mice [9, 10] .
In an effort to identify genetic polymorphisms in potential candidate genes for type 2 diabetes, we sequenced all exons in PCK1 and PCK2, including the −1.5 kb of the 5′ flanking region and ±50 bp exon-intron boundaries, and investigated associations with the risk of type 2 diabetes and diabetic phenotypes in a Korean population.
Subjects and materials
Subjects and measures A total of 775 unrelated patients with type 2 diabetes and 316 unrelated non-diabetic control subjects were recruited. Non-diabetic control subjects were recruited from an unselected population undergoing a routine health check-up at Seoul National University Hospital (Seoul, Korea). Inclusion criteria were as follows: 60 or more years of age, no past history of diagnosis of diabetes, no diabetes in first-degree relatives, fasting plasma glucose level <6.1 mmol/l and HbA 1 c<5.8%. The diabetic subjects were randomly recruited from patients attending the outpatient clinic of Seoul National University Hospital. Diabetes was diagnosed based on American Diabetes Association criteria [11] . Subjects who tested positive for anti-GAD antibodies were excluded. All subjects enrolled in this study were of Korean ethnicity. The study protocol was approved by the Institutional Review Board of the Clinical Research Institute at Seoul National University Hospital. Informed consent was obtained from all subjects before drawing blood samples. All study subjects were examined in the morning after an overnight fast. Height, weight, waist and hip circumferences and blood pressure were measured. Blood samples were drawn for biochemical measurements (fasting plasma glucose, postprandial 2-h glucose, fasting plasma insulin, HbA 1 c, total cholesterol, triglyceride, and HDL cholesterol) and DNA extraction. The insulin resistance index HOMA IR (homeostasis model assessment) was calculated as fasting serum insulin (mU/l)×fasting plasma glucose (mmol/l)/22.5 [12] . The clinical characteristics of the subjects are shown in Table 1 .
Sequencing analysis of the gene encoding human PCK We sequenced all exons, including exon-intron boundaries and the promoter region (∼1.5 kb), to discover single nucleotide polymorphisms (SNPs) in 24 Korean DNA samples using the ABI PRISM 3,700 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). Twenty-two primer sets for the amplification and sequencing analysis were designed based on GenBank sequences (Ref. Genotyping with fluorescence polarisation detection For genotyping of polymorphic sites, amplifying primers and probes were designed for TaqMan [13] . Primer Express (Applied Biosystems) was used to design both the PCR primers and the MGB TaqMan probes. One allelic probe was labelled with the FAM dye and the other with the fluorescent VIC dye. PCRs were run in the TaqMan Universal Master mix without UNG (Applied Biosystems), with PCR primer concentrations of 900 nmol/l and TaqMan MGB probe concentrations of 200 nmol/l. Reactions were performed in a 384-well format in a total reaction volume of 5 μl using 20 ng of genomic DNA. The plates then were placed in a thermal cycler (PE 9700; Applied Biosystems) and heated at 50°C for 2 min and 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The TaqMan assay plates were transferred to a Prism 7900HT instrument (Applied Biosystems) in which the fluorescence intensity in each well of the plate was read. Fluorescence data files from each plate were analysed using automated software (SDS 2.1; Applied Biosystems). Information regarding the primers is shown in ESM Table 2 .
Statistical analysis χ 2 Tests were used to determine whether the individual variant was in Hardy-Weinberg equilibrium at each locus in the population. Haplotypes and their frequencies were inferred using the algorithm developed by Stephens et al. [14] . Logistic regression analyses were used for calculating p values, controlling for age, sex and BMI as covariates. Multiple regressions, with adjustments for age, sex and BMI, were used for association analyses of metabolic phenotypes. Haplotype associations were analysed using the algorithm developed by Schaid et al. (Haplo.Score and Haplo.GLM) [15] , controlling for age, sex and BMI as covariates. The insulin and triglyceride levels were logarithmically transformed to normalise skewed distribution. Only non-diabetic subjects were used for association analyses of metabolic phenotypes, as treatment of type 2 diabetes may have affected the phenotypic values in the diabetic patients.
Results
Fourteen polymorphisms were identified in PCK1: five in the 5′ flanking region, two in introns, five in exons, and two in 3′ untranslated regions (UTRs). Eight polymorphisms were identified in PCK2: two in the 5′ flanking region, one in an intron, and four in exons (see ESM Table 3 ). The locations and allele frequencies of identified polymorphic sites are shown in Fig. 1a and b. By pair-wise linkage analysis with 24 Korean DNA samples, which were used for direct sequencing, we found that two sets of SNPs in PCK1 were in absolute linkage disequilibrium (LD) (|D′|=1 and r 2 =1) (see Fig. 1a ).
Among the identified polymorphisms, six SNPs in PCK1 (+69A>G, +1428C>G,+1573G>C, +3404T>C, +4513T>G and +4824T>C) and four SNPs in PCK2 (−403C>T, +3894T>C, +5804A>G and +8881C>G) were selected for larger-scale genotyping based on location (SNPs in exons were preferred), LD (only one SNP if there are absolute LDs), frequency (>0.05) and haplotype tagging status. A >97% genotyping success rate was obtained (on average) by the TaqMan method. Genotyping quality control was performed by duplicate checking of 10% of the samples. No mismatches were detected among duplicates. Six common haplotypes in PCK1 and four common haplotypes in PCK2 were constructed in a Korean population (Fig. 1b,d) . Table 3 ).
The genotype distributions of all loci were in HardyWeinberg equilibrium (p>0.05, ESM Table 3 ). Among common haplotypes identified among the Korean population, only those with frequencies >0.05 were used for further analysis (Fig. 1b,d ). Haplotypes that were mostly (>90%) tagged by single SNPs were not used for further analysis (ht2 in PCK1, ht3 in PCK2).
Associations of PCK polymorphisms with the risk of type 2 diabetes and diabetic phenotypes were analysed using logistic and multiple regressions, adjusting for age, sex and BMI (775 type 2 diabetic patients and 316 normal control subjects). The clinical characteristics of subjects are shown in Table 1 . Our study was designed to detect common variants that might be involved in the risk of type 2 diabetes and relative phenotypes. Only non-diabetic subjects were used for association analyses of metabolic phenotypes, including cholesterol, log-transformed triglyceride, HDL, log-transformed insulin and BMI, because treatment for type 2 diabetes may affect these values.
Although no significant associations between the genetic polymorphisms in PCK genes and the risk of type 2 diabetes were detected, in further haplotype analysis one of the common haplotypes, PCK1 ht3, revealed susceptibility to type 2 diabetes (p=0.006, Table 2 ).
No reliable associations were detected with fasting blood sugar, BMI, insulin, HOMA IR and WHR (see ESM Table 4 ). However, several SNPs and haplotypes have significant correlations with various metabolic traits (cholesterol: PCK1+3404T>C and PCK1 ht1; log-transformed triglyceride: PCK1+4824T>C and PCK1 ht1; HDL: +1428C>G, +4824T>C and PCK1 ht3) ( Table 3) . Among them, one 3′ UTR SNP, +4824T>C, showed a gene-dose-dependent association with HDL levels among non-diabetic control subjects: individuals who were homozygous for the major allele (T/T) had the lowest HDL level (1.11±0.32 mmol/l), heterozygotes (T/C) had an intermediate level (1.27± 0.37 mmol/l), and individuals homozygous for the minor allele (C/C) had the highest level (1.39±0.28 mmol/l) (p=0.000003, Table 3 ). In addition, this 3′ UTR SNP was also associated with triglyceride levels; a lower triglyceride level was found among individuals who were homozygous for the minor allele (C/C) than those who were not.
In additional analysis, 3′ UTR SNP and PCK1 ht3 also showed significant association (p=0.002 and 0.0002, respectively) with BMI among diabetic subjects, but these significant associations were unreliable because the treatment for type 2 diabetes might have affected the phenotypic values in diabetics (see ESM Table 5 ).
Discussion
In a previous report [16] , one promoter SNP (−232C>G; − 534C>G in this study), which is in absolute LD (|D′|=1 and r 2 =1) with three nearby SNPs (−1,399C>T, −1,269 C>T, −534C>G, +69A>G, Fig. 1a) , was reported to be associated with the risk of type 2 diabetes in both Oji-Cree and Caucasian populations. However, no significant association was revealed in the Korean population. PCK1 ht3 only showed significant association with the risk of type 2 diabetes. Although it is hard to decipher the discrepancies between the previous study and the present study, a dif- In the present study, the significance of the association (p=0.000003 in the co-dominant model) between HDL and this 3′ UTR SNP (PCK1+4824T>C) was retained even after the strictest correction for multiple tests (170 tests: 17 comparisons in case-control, 17 comparisons in five different diabetic phenotypes [cholesterol, triglyceride, HDL, insulin and BMI] with three alternative analysing models [co-dominant, dominant and recessive models]).
Although the mechanisms involved in the different HDL and triglyceride levels associated with the alternative genotypes in the 3′ UTR are not currently understood, there are several possible explanations. The crucial role of the noncoding portion of genomes is now widely acknowledged. In particular, mRNA UTRs are involved in many post-transcriptional regulatory pathways that control mRNA localisation, stability and translation efficiency. Initiation of protein synthesis could be influenced by sequence elements in both 5′ and 3′ UTRs. The post-transcriptional events play an important yet incompletely understood role in regulatory gene expression and cellular behaviour; many of the identified cis-acting elements for translational regulation occur within the 3′ UTR [17] .
Recent data suggest that PCK1 is involved in glyceroneogenesis as well as gluconeogenesis [1, 2] . Glyceroneogenesis in both liver and adipose tissue is the de novo synthesis of glycerol 3-phosphate from gluconeogenic precursors. Each glycerol 3-phosphate is used to esterify fatty acyl-CoA to form triglyceride. It has been shown that mice lacking hepatic PCK1 develop fatty livers and have elevated plasma fatty acids and triglyceride levels following a fast [1, 5, 6] . It has also been reported that removal of PCK1 results in an increase in the mitochondrial redox state and dramatic inhibition of the TCA cycle, which results in reduced oxidation of fats via beta oxidation, reduced production of ketones and subsequent hepatic steatosis [18] . These results suggest that mutations in PCK1 may affect glyceroneogenesis and/or cataplerosis, which would affect the storage and release of fatty acids. Further biological and/or functional evidence would be needed to clarify the mechanism(s) involved in different blood HDL and triglyceride levels mediated by alternative PCK1 polymorphisms.
In summary, 22 polymorphisms in PCK1 and PCK2 were identified in a Korean population (n=24) by direct DNA sequencing. Associations of PCK polymorphisms with the risk of type 2 diabetes and diabetic phenotypes were analysed using logistic and multiple regression analyses, with adjustment for age, sex and BMI. Although no significant associations between the genetic polymorphisms in PCK genes and the risk of type 2 diabetes were detected, it was revealed that PCK1 ht3 is significantly associated with the risk of type 2 diabetes (p=0.006). One 3′ UTR SNP, +4824T>C, was strongly associated with HDL and triglyceride levels among non-diabetic control subjects (p=0.000003).
Although the statistical power to detect significant association of this study (775 type 2 diabetic patients and 316 normal control subjects) might be low for rare variants, our study was designed to detect common variants that might be involved in the risk of type 2 diabetes. In addition, the differences in quantitative traits (which are dependent on sample sizes [genotype distributions], means of traits and SDs among populations) among 316 normal controls might not be detected, especially for rare allele (e.g. unequal sample sizes for populations).
Although our results showed several significant associations of polymorphisms with various metabolic traits (cholesterol, log-transformed triglyceride and HDL), replication of our finding in an independent dataset and/or functional validation of polymorphisms should be performed in the future. The strong association of HDL and triglyceride levels with the PCK1 polymorphism and the variation/haplotype information identified in this study would be useful for genetic epidemiological studies of other metabolic diseases.
